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Abstract A formal asymmetric synthesis of both enantiomers of the Erythrina alkaloid 3-
demethoxyerythratidinone is reported through the application of a highly functionalised lactam template as 
an N-acyliminium precursor.  
 1, 3-demethoxyerythratidinone erythramine erysotramidine 
The genus Erythrina is common in tropical and subtropical regions and the alkaloids have been 
used in indigenous medicine.1 Members of the Erythrina family display curare-like and hypnotic 
activity, and a variety of pharmacological effects are associated with the erythrinane skeleton 
including sedative, hypotensive, neuromuscular blocking and CNS activity.2a Consequently there 
has been much interest in the synthesis of these alkaloids and derivatives (including 
pyrroloisoquinoline precursors) over recent years.2 
3-Demethoxyerythratidinone, 1, was isolated from Erythrina Lithosperma in 1973 by Barton and 
co-workers.3 Despite being structurally one of the simplest of the Erythrina class of alkaloid, it 
was not until 1984 that Tsuda reported the first total synthesis, in racemic form, of this natural 
product.4 Almost a decade later this same group reported an asymmetric route to the enantiomeric 
form of the natural product, the so-called “enantio-(−)-3-demethoxyerythratidinone”.5 
We have recently concerned ourselves with the development of novel, efficient and 
stereoselective routes to complex heterocyclic targets by employing N-acyliminium intermediates 
in cyclisation reactions.6 In a recent publication6a we detailed a novel approach to an erythrinane-
like ring system through the application of a Meyers chiral lactam template. We now wish to 
report the successful application of our methodology to construct a functionalised erythrinane 
ring system in a highly stereoselective manner, thus representing a formal asymmetric synthesis 
of both enantiomers of the natural product, 3-demethoxyerythratidinone. 
Although the chiral lactams pioneered by Meyers have been widely utilised in asymmetric 
synthesis,7 to the best of our knowledge the present application, as a precursor in an N-
acyliminium mediated cyclisation reaction leading to erythrinane targets, represents a novel use 
of this popular chiral template. In order to access the more highly functionalised alkaloid skeleton 
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we were required to prepare the protected keto-acid substrate 3. This compound was readily 
accessed by enolate alkylation and subsequent ester group hydrolysis of the commercially 
available mono-protected diketone 2, as shown in Scheme 1. 
 2 Scheme 1 3 
Our synthesis of the required lactam substrate 5 then followed similar methodology to that 
previously described by us,6 with the required β-aminoalcohol 4 prepared in 97% yield by 
reduction of the commercially available amino acid, 3-(3,4-dimethoxyphenyl)-L-alanine, with 
LiBH4 in the presence of Me3SiCl in THF for 24 hours at room temperature. Condensation of 
substrates 3 and 4 under Dean-Stark conditions in toluene for 48 hours gave a 63% yield of the 
desired lactam 5 as a single diastereoisomer (Scheme 2). The formation of a single product 
diastereoisomer of lactam 5 from the racemic keto acid 3 requires the epimerisation of the 
stereogenic centre adjacent to the ketone during the reaction, and this fact has been noted 
previously for similar substrates in the preparation of polycyclic lactams for use as N-
acyliminium precursors.6a,8 
With 5 in hand, we turned our attention to the proposed asymmetric cyclisation. On treating 
lactam 5 with 3 equivalents of TiCl4 as Lewis acid activator at low temperature in 
dichloromethane for 20 hours we were pleased to isolate the tetracyclic product 6 in an excellent 
92% yield. Perhaps not unexpectedly, the cyclisation under strong Lewis acid conditions had 
been accompanied by concomitant deprotection of the ketal protecting group. Reducing the 
number of equivalents of the Lewis acid did not result in selective formation of the corresponding 
cyclisation product with the ketal group intact, and instead an inseparable product mixture was 
obtained. Indeed, since the removal of the protecting group did not hinder the immediate progress 
of our work, we favoured the use of excess Lewis acid to achieve clean and complete 
deprotection at this stage. 1H-NMR Analysis of the crude product mixture revealed the formation 
of a 10:1 mixture of product diastereoisomers.  
Scheme 2 
The major diastereoisomer 6 was isolated by column chromatography. In our previous work on 
the synthesis of the related compound 7, prepared by analogous chemistry, we were able to 
determine the relative stereochemistry by X-ray crystallography. In this present case we were 
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unable to obtain suitable crystals for X-ray, however the absence of an NOE between the protons 
at positions 4 and 13a supports the proposed structure; one would not expect a change in product 
stereochemistry to be favoured on simply introducing the remote protecting group in this current 
series. The stereochemical outcome of this cyclisation reaction can be rationalised using the same 
conformational model previously proposed by our group for related cyclisations.6 The presence of 
an asymmetric centre next to the iminium carbon may also act to influence the formation of the 
new chiral centre on cyclisation. If this were to be a contributing factor, one can appreciate that 
the aromatic ring approaches the planar acyliminium intermediate from the direction of least 
steric hindrance. 
Removal of the pendant hydroxymethyl substituent (auxiliary) from the tetracyclic product 6 was 
achieved by application of a three-step procedure (Scheme 3). Dess-Martin periodinane oxidation 
of the primary alcohol proceeded in 93% yield to provide aldehyde 8. We then employed our 
favoured Rh-catalyzed decarbonylation protocol to access enamide 9 in 55% yield; a small 
amount of target compound 10 (6%) was also produced directly in this reaction. The auxiliary 
removal sequence was completed by catalytic hydrogenation of the crude mixture from the 
previous step to furnish the amidoketone 10 in 79% yield.  
Scheme 3. (i) Dess-Martin periodinane, DCM; (ii) Rh(PPh3)2(CO)Cl, dppp, mesitylene, Δ, 4 days;  
(iii) H2/10% Pd-C, EtOH; (iv) ethylene glycol, pTSA (cat.), toluene, Δ. 
The formal asymmetric synthesis of (+)-demethoxyerythratidinone, the natural enantiomer, 
simply required re-protection of the ketone functional group using ethylene glycol as shown in 
Scheme 3. Compound 11 has been converted by others to the natural product albeit in racemic 
form by a 4-step sequence.4 
The formal asymmetric synthesis of the unnatural enantiomer followed an identical synthetic 
route, beginning however with the enantiomeric form of the original amino acid substrate to 
access the required lactam substrate 12, which had the opposite optical rotation value to that 
obtained for lactam 5. Intermediate 13 gave an optical rotation of +39.6, compared to –36.9 for 
compound 10. The enantio-target 14, gave an optical rotation of +21.7, compared to –26.1 for 
compound 11 (all measured at slightly altered concentrations).  
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To summarize, we report the first synthetic application of our recently developed asymmetric N-
acyliminium cyclisation methodology in natural product chemistry. Our approach allows a facile 
and highly stereoselective formal synthesis of both enantiomers of the alkaloid 3-
demethoxyerythratidinone.  
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